April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
November 2023 in “Open Repository of the University of Porto (University of Porto)” Community pharmacies and pharmacists play a crucial role in improving community health.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
April 2024 in “International journal of clinical trials” SesZen-Bio™ improves hair density, thickness, and overall hair health.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
August 2002 in “Inpharma Weekly”
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
6 citations
,
October 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Early treatment improved COVID-19 outcomes, and spironolactone helped reduce risks in females with high androgen levels.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
211 citations
,
May 2013 in “Journal of Nutrition Health & Aging” MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
April 2011 in “Reactions Weekly” 5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” 4 citations
,
April 2004 in “Medical veritas” Zinc can reverse hair loss caused by the anthrax vaccine.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
2 citations
,
March 2015 in “Clinical and Experimental Dermatology” Azathioprine can cause unusual hair loss, which may reverse after stopping the drug.
64 citations
,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
3 citations
,
April 2003 in “BJUI” Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.